Geron (NASDAQ:GERN) & MDxHealth (NASDAQ:MDXH) Critical Analysis

Geron (NASDAQ:GERN) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Risk and Volatility

Geron has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

Profitability

This table compares Geron and MDxHealth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Geron	-23.04%	-16.33%	-6.77%
MDxHealth	-33.46%	N/A	-24.25%

Analyst Ratings

This is a summary of current recommendations for Geron and MDxHealth, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1	2	3	0	2.33
MDxHealth	1	4	1	0	2.00

Geron currently has a consensus target price of $3.75, indicating a potential upside of 276.13%. MDxHealth has a consensus target price of $1.33, indicating a potential upside of 760.22%. Given MDxHealth’s higher possible upside, analysts clearly believe MDxHealth is more favorable than Geron.

Valuation & Earnings

This table compares Geron and MDxHealth”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88 million	3.48	-$83.50 million	($0.08)	-12.46
MDxHealth	$107.88 million	0.07	-$33.52 million	($0.72)	-0.22

MDxHealth has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

73.7% of Geron shares are owned by institutional investors. 1.7% of Geron shares are owned by company insiders. Comparatively, 1.7% of MDxHealth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Geron beats MDxHealth on 9 of the 14 factors compared between the two stocks.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.